[The first experience of intravitreal injection of Lucentis (ranibizumab) in the moist form of age-related maculodystrophy].
The aim of the study was to evaluate the efficiency of intravitreal injection of Lucentis (ranibizumab) for the treatment of varying forms of chorioidal neovascularization (CNV). One hundred and six patients with the moist form of age-related maculodystrophy in whom 187 intravitreal Lucentis injections were made were examined. With a good response to treatment, the intravitreal injection of ranibizumab makes it possible to reduce the retinal thickness of the macula and to achieve arrest or less progression of CNV in patients with different stages of a process.
Baĭborodov
Ia V
IaV
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D000069579:Ranibizumab; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab